Two drug giants are joining TrumpRx with discounts so steep they spotlight an uncomfortable truth: Washington’s health-care “system” still leaves millions paying the highest prices simply because they’re uninsured.
Quick Take
- AbbVie and Genentech are set to begin offering discounted medications through the White House’s TrumpRx website, becoming the 10th and 11th participating companies.
- AbbVie’s Humira is listed at $950—an 86% discount compared with a reported list price of more than $6,900 for uninsured patients paying cash.
- Genentech’s Xofluza (flu treatment) is set at $50, down from a reported $168.
- Eligibility is limited to uninsured people or patients who pay full out-of-pocket costs without insurance coverage, leaving most insured Americans outside the program.
AbbVie and Genentech expand TrumpRx’s drug list and political stakes
AbbVie and Genentech will officially launch select products on the TrumpRx website, according to reporting that describes the companies as the 10th and 11th to join the platform.
The White House-backed site went live in February 2026 with roughly 40 drugs and now lists more than 61, reflecting a rapid expansion strategy that relies on negotiated, direct-to-consumer discounts rather than insurance-driven pricing.
CBS News Exclusive: Drug-making giants Abbvie and Genentech will start selling medications at a discount soon on TrumpRx. https://t.co/vo4KCd2bkX
— CBS News (@CBSNews) April 6, 2026
TrumpRx’s newest headliners are drugs that have long symbolized why patients distrust the pricing chain.
AbbVie’s Humira (adalimumab), used for conditions including rheumatoid arthritis and Crohn’s disease, is priced at $950 through the program.
It represents an 86% reduction compared to a list price of more than $6,900 for uninsured cash-pay patients. Genentech, a Roche subsidiary, is offering the flu medication Xofluza at $50, down from $168.
How TrumpRx works: a direct discount lane aimed at the uninsured
TrumpRx is positioned as a White House platform that aggregates manufacturer discounts and routes patients to lower prices without relying on traditional insurance negotiations.
That design choice matters because it targets the group most exposed to list prices: people without insurance or those paying fully out-of-pocket.
In practice, it also means the program does not resolve the complaints many insured families have about premiums, deductibles, and pharmacy benefit manager rules.
Eligibility limits are the center of both the appeal and the critique. For uninsured patients who qualify, the savings can be immediate and easy to understand: pay the TrumpRx price rather than the list price.
For insured Americans, the same drugs may already be subject to confidential rebates and negotiated rates, but patients often experience those savings indirectly—or not at all—depending on plan design. The reporting available does not quantify how many patients will use TrumpRx or how consistently pharmacies honor the discounts.
Timeline shows negotiations, not legislation, driving the price cuts
The sequence described in reporting emphasizes deal-making over sweeping statutory reform. The White House announced the Genentech arrangement in December 2025, followed by an agreement with AbbVie in January 2026. TrumpRx then launched in February 2026 and has expanded since.
In early April 2026, new reporting said the AbbVie and Genentech listings would go live “as soon as Monday,” while Amgen also expanded offerings to include Enbrel and Otezla.
At the same time, the limited scope highlights why frustration with federal health policy cuts across party lines. A program can deliver real relief to a specific population and still leave the broader pricing ecosystem largely intact—especially if most Americans remain outside the eligibility rules by design.
What this means for voters who distrust elites and the health-care middlemen
TrumpRx’s growth is likely to energize supporters who view drug pricing as a symbol of elite capture—where manufacturers, insurers, and middlemen benefit while ordinary patients struggle.
The reported Humira and Xofluza discounts are concrete numbers voters can judge. Yet the available reporting also underlines a limitation: TrumpRx primarily addresses the uninsured cash-pay problem, not the full set of cost drivers that inflate premiums and out-of-pocket spending inside employer and marketplace plans.
The political significance may be less about one website and more about the precedent: a White House directly brokering discounts from major companies and publicizing list-price reductions.
That can pressure additional firms to participate, particularly if they fear tougher regulatory moves or reputational damage.
Sources:
Two more pharmaceutical companies, Abbvie and Genentech, to officially launch on TrumpRx
Two more drug companies to officially launch on TrumpRx
